<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Markland AD</submitter><funding>NCATS NIH HHS</funding><funding>NCCIH NIH HHS</funding><funding>NIA NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NCI NIH HHS</funding><pagination>243-252</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9742141</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>209(1)</volume><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Our goal was to evaluate vitamin D supplementation for preventing or treating overactive bladder and urinary incontinence in men.&lt;h4>Materials and methods&lt;/h4>Ancillary study of men aged ≥55 years in VITAL (VITamin D and OmegA-3 TriaL). Randomized treatments included: vitamin D&lt;sub>3&lt;/sub> (cholecalciferol), marine omega-3 fatty acids, or matching placebo. Structured urinary incontinence questions measured the prevalence of overactive bladder at year 5 and urinary incontinence at years 2 and 5, along with incidence and progression of urinary incontinence from years 2 to 5. Prespecified subgroup analyses examined men with low baseline serum 25-hydroxyvitamin D (&lt;20 ng/mL).&lt;h4>Results&lt;/h4>Among the 11,486 men who provided data at year 2 and 10,474 at year 5, mean age was 68 years at year 2, with 23% racial/ethnic minorities. In primary analyses, vitamin D supplementation compared to placebo did not lower odds of overactive bladder at year 5 (OR 0.97, 95% CI 0.87-1.08) or weekly urinary incontinence at year 2 (OR 0.94, 95% CI 0.83-1.05) or year 5 (OR 0.98, 95% CI 0.88-1.09). We found interactions of baseline serum 25-hydroxyvitamin D level with vitamin D supplementation for overactive bladder (&lt;i>P&lt;/i> value for interaction = .001), and secondarily, for any urinary incontinence at year 2 (&lt;i>P&lt;/i> value for interaction = .05). Men with baseline 25-hydroxyvitamin D &lt;20 ng/mL, who were assigned to vitamin D supplements, had lower odds of overactive bladder (OR 0.51, 95% CI 0.35-0.76) compared to placebo, yet higher odds of any urinary incontinence (OR 1.24, 95% CI 0.93-1.64).&lt;h4>Conclusions&lt;/h4>Overall, vitamin D supplementation did not improve overactive bladder or urinary incontinence compared to placebo. However, specific use of vitamin D in men with lower 25-hydroxyvitamin D levels had inconsistent findings.</pubmed_abstract><journal>The Journal of urology</journal><pubmed_title>Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial.</pubmed_title><pmcid>PMC9742141</pmcid><funding_grant_id>R01 AT011729</funding_grant_id><funding_grant_id>U01 CA138962</funding_grant_id><funding_grant_id>R01 CA138962</funding_grant_id><funding_grant_id>UL1 TR002378</funding_grant_id><funding_grant_id>K24 AG073586</funding_grant_id><funding_grant_id>R01 DK115473</funding_grant_id><funding_grant_id>K24 AG068601</funding_grant_id><pubmed_authors>Tangpricha V</pubmed_authors><pubmed_authors>Vaughan CP</pubmed_authors><pubmed_authors>Bubes VY</pubmed_authors><pubmed_authors>Manson JE</pubmed_authors><pubmed_authors>Cook NR</pubmed_authors><pubmed_authors>Lee IM</pubmed_authors><pubmed_authors>Kim E</pubmed_authors><pubmed_authors>Buring JR</pubmed_authors><pubmed_authors>Markland AD</pubmed_authors><pubmed_authors>Grodstein F</pubmed_authors><pubmed_authors>Huang AJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of Vitamin D Supplementation on Overactive Bladder and Urinary Incontinence Symptoms in Older Men: Ancillary Findings From a Randomized Trial.</name><description>&lt;h4>Purpose&lt;/h4>Our goal was to evaluate vitamin D supplementation for preventing or treating overactive bladder and urinary incontinence in men.&lt;h4>Materials and methods&lt;/h4>Ancillary study of men aged ≥55 years in VITAL (VITamin D and OmegA-3 TriaL). Randomized treatments included: vitamin D&lt;sub>3&lt;/sub> (cholecalciferol), marine omega-3 fatty acids, or matching placebo. Structured urinary incontinence questions measured the prevalence of overactive bladder at year 5 and urinary incontinence at years 2 and 5, along with incidence and progression of urinary incontinence from years 2 to 5. Prespecified subgroup analyses examined men with low baseline serum 25-hydroxyvitamin D (&lt;20 ng/mL).&lt;h4>Results&lt;/h4>Among the 11,486 men who provided data at year 2 and 10,474 at year 5, mean age was 68 years at year 2, with 23% racial/ethnic minorities. In primary analyses, vitamin D supplementation compared to placebo did not lower odds of overactive bladder at year 5 (OR 0.97, 95% CI 0.87-1.08) or weekly urinary incontinence at year 2 (OR 0.94, 95% CI 0.83-1.05) or year 5 (OR 0.98, 95% CI 0.88-1.09). We found interactions of baseline serum 25-hydroxyvitamin D level with vitamin D supplementation for overactive bladder (&lt;i>P&lt;/i> value for interaction = .001), and secondarily, for any urinary incontinence at year 2 (&lt;i>P&lt;/i> value for interaction = .05). Men with baseline 25-hydroxyvitamin D &lt;20 ng/mL, who were assigned to vitamin D supplements, had lower odds of overactive bladder (OR 0.51, 95% CI 0.35-0.76) compared to placebo, yet higher odds of any urinary incontinence (OR 1.24, 95% CI 0.93-1.64).&lt;h4>Conclusions&lt;/h4>Overall, vitamin D supplementation did not improve overactive bladder or urinary incontinence compared to placebo. However, specific use of vitamin D in men with lower 25-hydroxyvitamin D levels had inconsistent findings.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-05-28T01:55:41.371Z</modification><creation>2025-04-04T03:00:15.721Z</creation></dates><accession>S-EPMC9742141</accession><cross_references><pubmed>36067369</pubmed><doi>10.1097/JU.0000000000002942</doi><doi>10.1097/ju.0000000000002942</doi></cross_references></HashMap>